Holen Sie sich die Stockscreener-App
17.10
4.58%
-0.82
Handel nachbörslich:
17.28
0.18
+1.05%
Schlusskurs vom Vortag:
$17.92
Offen:
$18.09
24-Stunden-Volumen:
1.60M
Relative Volume:
1.45
Marktkapitalisierung:
$1.16B
Einnahmen:
$2.73B
Nettoeinkommen (Verlust:
$-1.13B
KGV:
-1.0263
EPS:
-16.6622
Netto-Cashflow:
$-83.00M
1W Leistung:
-17.91%
1M Leistung:
-27.48%
6M Leistung:
-40.15%
1J Leistung:
-51.97%
1-Tages-Spanne:
$17.08
$18.63
1-Wochen-Bereich:
$17.08
$20.24
52-Wochen-Spanne:
$17.08
$38.99
Quidelortho Corporation Stock (QDEL) Company Profile
Firmenname
Quidelortho Corporation
Sektor
Branche
Telefon
(858) 552-1100
Adresse
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
17.10 | 1.22B | 2.73B | -1.13B | -83.00M | -16.66 |
|
ABT
Abbott Laboratories
|
108.03 | 187.91B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
336.77 | 129.05B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.14 | 112.19B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.13 | 101.72B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.81 | 49.14B | 6.07B | 1.06B | 1.34B | 1.8063 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-08 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-09-19 | Fortgesetzt | UBS | Neutral |
| 2024-09-05 | Hochstufung | Craig Hallum | Hold → Buy |
| 2024-03-04 | Herabstufung | UBS | Neutral → Sell |
| 2024-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-14 | Hochstufung | UBS | Sell → Neutral |
| 2022-09-19 | Eingeleitet | Citigroup | Neutral |
| 2022-07-20 | Eingeleitet | UBS | Sell |
| 2022-06-17 | Fortgesetzt | JP Morgan | Neutral |
| 2022-02-22 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-01-22 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-26 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-10-23 | Fortgesetzt | Raymond James | Strong Buy |
| 2018-03-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-01-22 | Bestätigt | Barclays | Overweight |
| 2018-01-04 | Hochstufung | CL King | Neutral → Buy |
| 2017-09-19 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-07-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-07-18 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-04-25 | Bestätigt | Canaccord Genuity | Hold |
| 2017-02-17 | Eingeleitet | CL King | Neutral |
| 2016-12-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-06-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2016-02-18 | Bestätigt | Barclays | Overweight |
| 2016-02-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2016-01-08 | Bestätigt | Canaccord Genuity | Buy |
| 2015-12-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-09-02 | Eingeleitet | Barclays | Overweight |
| 2013-07-31 | Bestätigt | Canaccord Genuity | Buy |
| 2011-03-03 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Quidelortho Corporation Aktie (QDEL) Neueste Nachrichten
Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report? - Yahoo Finance
QuidelOrtho (QDEL) Valuation Check After Prolonged Share Price Weakness And Earnings Challenges - Yahoo Finance
QuidelOrtho Corp. Hits New 52-Week Low at $18.94 Amid Ongoing Struggles - Markets Mojo
QuidelOrtho Corp. Stock Plummets to New 52-Week Low of $19.24 - Markets Mojo
QuidelOrtho Corp. Forms Death Cross, Signaling Potential Bearish Trend - Markets Mojo
Chipmakers Recap: Will QuidelOrtho Corporation benefit from AI trends2026 Technical Patterns & Low Risk High Reward Ideas - baoquankhu1.vn
Stock Recap: Is QuidelOrtho Corporation a defensive stock2026 Earnings Impact & Daily Profit Focused Screening - baoquankhu1.vn
QuidelOrtho (NASDAQ:QDEL) Hits New 1-Year LowHere's Why - MarketBeat
Rice Hall James Buys QuidelOrtho Stock - The Motley Fool
Rice Hall James Buys QuidelOrtho Stock - The Motley Fool
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes shares are falling, what you need to know - MSN
Rate Cut: Is QuidelOrtho Corporation a turnaround story2025 Bull vs Bear & Weekly High Conviction Trade Ideas - baoquankhu1.vn
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Yahoo Finance
American Century Companies Inc. Raises Stock Position in QuidelOrtho Corporation $QDEL - MarketBeat
QuidelOrtho at Raymond James Conference: Strategic Growth Insights - Investing.com Nigeria
QuidelOrtho at Raymond James Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
QuidelOrtho Stock Challenges: Revenue, Cash Flow, and ROIC TrendsNews and Statistics - IndexBox
A Look At QuidelOrtho (QDEL) Valuation After New Lifotronic Supply Agreement - Sahm
QuidelOrtho Corporation (QDEL) Stock Analysis: Potential Upside of Over 50% Amidst Strategic Positioning in Healthcare - DirectorsTalk Interviews
Segall Bryant & Hamill LLC Sells 71,044 Shares of QuidelOrtho Corporation $QDEL - MarketBeat
QuidelOrtho (QDEL): Buy, Sell, or Hold Post Q4 Earnings? - Barchart.com
Vanguard Group Inc. Has $224.89 Million Stock Position in QuidelOrtho Corporation $QDEL - MarketBeat
QuidelOrtho Corp reports results for the quarter ended March 31Earnings Summary - TradingView
QuidelOrtho (QDEL) Q4 2025 Earnings Transcript - AOL.com
QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires - AOL.com
QuidelOrtho Corporation (NASDAQ:QDEL) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
QuidelOrtho Q4 2025 slides: Revenue beats expectations despite 27% EPS drop - Investing.com Nigeria
Should QuidelOrtho’s (QDEL) Lifotronic Immunoassay Expansion Require Action From QDEL Investors? - simplywall.st
Why The QuidelOrtho (QDEL) Story Is Shifting As Analysts Rework Growth And Valuation Assumptions - Yahoo Finance
Is QuidelOrtho Corporation a defensive stockJuly 2025 Price Swings & Verified Swing Trading Watchlists - baoquankhu1.vn
Has QuidelOrtho (QDEL) Become A Potential Opportunity After Its Sharp Share Price Slide - simplywall.st
QuidelOrtho Corp. Stock Hits Day Low of $21.14 Amid Price Pressure - Markets Mojo
QuidelOrtho Corporation (QDEL) Stock Analysis: Exploring a 63.60% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
Earnings Miss: Is QuidelOrtho Corporation a defensive stock2025 Volatility Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know - Finviz
QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2025 earnings call transcript - MSN
Quidelortho Faces Material Risk from Weak Internal Controls and Sarbanes–Oxley Compliance Challenges - TipRanks
Decoding QuidelOrtho Corp (QDEL): A Strategic SWOT Insight - GuruFocus
Can QuidelOrtho’s (QDEL) Lifotronic Deal Reshape Its Global Immunoassay Competitiveness Story? - Yahoo Finance
Faster Cardiac Answers with High‑Sensitivity Troponin - PR Newswire
QuidelOrtho and Lifotronic agree on global immunoassay portfolio expansion - MSN
QuidelOrtho (NASDAQ:QDEL) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
QuidelOrtho Corp SEC 10-K Report - TradingView
QuidelOrtho Earnings Call: Growth, Margins And Risks - TipRanks
QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference - marketscreener.com
The Top 5 Analyst Questions From QuidelOrtho's Q4 Earnings Call - Finviz
QuidelOrtho Partnership Targets Expanded Immunoassay Reach in International Markets - TipRanks
QuidelOrtho–Lifotronic Partnership Targets Global Immunoassay Expansion - TipRanks
QuidelOrtho–Lifotronic Partnership Targets Immunoassay Expansion in International Markets - TipRanks
Finanzdaten der Quidelortho Corporation-Aktie (QDEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Quidelortho Corporation-Aktie (QDEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Busky Joseph M. | Chief Financial Officer |
Feb 13 '26 |
Buy |
23.66 |
3,370 |
79,742 |
10,290 |
| Blaser Brian J. | President and CEO |
Feb 13 '26 |
Buy |
23.59 |
10,540 |
248,661 |
40,073 |
| RHOADS ANN D | Director |
Dec 10 '25 |
Buy |
28.27 |
750 |
21,206 |
15,021 |
| Wilkins Joseph D Jr. | Director |
Nov 26 '25 |
Buy |
27.95 |
370 |
10,343 |
11,876 |
| WIDDER KENNETH J | Director |
Nov 25 '25 |
Option Exercise |
15.74 |
7,021 |
110,511 |
41,087 |
| WIDDER KENNETH J | Director |
Nov 25 '25 |
Sale |
27.81 |
4,026 |
111,965 |
37,061 |
0.66%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):